Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

Thrombosis Journal

Anthonie W. A. Lensing¹  Wolfgang Mück²  Jan Stampfuss²  Katrin Coboeken³  Jörg Lippert³  Dagmar Kubitza⁴  Rolf Burghaus⁴  Stefan Willmann⁴  Kirstin Thelen⁴  Matthias Frede⁴ 

[1] Clinical Development, Bayer AG;Clinical Pharmacology, Bayer AG;Clinical Pharmacometrics, Bayer AG;Clinical Sciences, Bayer AG;

关键词: Pediatric;    Pharmacokinetics;    Physiologically based pharmacokinetic modelling;    Rivaroxaban;   

DOI  :  10.1186/s12959-018-0185-1

来源: DOAJ

【 摘 要 】

Abstract Background The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pharmacokinetic (PBPK) model for pediatric rivaroxaban dosing has been constructed. Methods We quantitatively assessed the pharmacokinetics (PK) of a single rivaroxaban dose in children using population pharmacokinetic (PopPK) modelling and assessed the applicability of the PBPK model. Plasma concentration–time data from the EINSTEIN-Jr phase I study were analysed by non-compartmental and PopPK analyses and compared with the predictions of the PBPK model. Two rivaroxaban dose levels, equivalent to adult doses of rivaroxaban 10 mg and 20 mg, and two different formulations (tablet and oral suspension) were tested in children aged 0.5–18 years who had completed treatment for VTE. Results PK data from 59 children were obtained. The observed plasma concentration–time profiles in all subjects were mostly within the 90% prediction interval, irrespective of dose or formulation. The PopPK estimates and non-compartmental analysis-derived PK parameters (in children aged ≥6 years) were in good agreement with the PBPK model predictions. Conclusions These results confirmed the applicability of the rivaroxaban pediatric PBPK model in the pediatric population aged 0.5–18 years, which in combination with the PopPK model, will be further used to guide dose selection for the treatment of VTE with rivaroxaban in EINSTEIN-Jr phase II and III studies. Trial registration ClinicalTrials.gov number, NCT01145859; registration date: 17 June 2010.

【 授权许可】

Unknown